Empowering AAV quantification for gene therapy research

Adeno-associated virus (AAV) vectors have become a cornerstone of gene therapy, valued for their safety, broad targeting capabilities, and adaptability across therapeutic applications.

In this application note, Abselion demonstrates the Amperia™ platform, offering a streamlined alternative – using a sandwich-format assay with high-affinity antibodies from Thermo Fisher Scientific to quantify multiple AAV serotypes with robust performance across sample types.